Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty process development and production services to the worldwide nutraceuticals, cosmetics, biotherapeutics and food/beverage industries, has entered an execution and launch agreement with CBD Supply MD, one of the largest and best-known retail suppliers of CBD products in the multistate mid-Atlantic region. Based on the agreement, PBIO will provide its UltraShear(TM) optimized nanoemulsions of CBD in a high-quality CBD topical spray and CBD Supply MD will introduce PBIO’s CBD products across the multistate Mid-Atlantic region. The agreement, which is projected to bring in more than $1.5 million in revenue for PBIO this year, outlines four phases of product development and commercialization for the product, with phase 1 already underway; the agreement calls for an initial shipment of 850 vials of the exclusive UltraShear-nanoemulsified CBD by mid-April 2023. “Our diverse work on UltraShear nanoemulsion processing across nutraceutical, cosmeceutical, pharmaceutical, food/beverage and agrochemical markets has generated an exciting array of developing commercial opportunities for PBI,” said Pressure BioSciences president and CEO Richard T. Schumacher in the press release. “We have foreshadowed a plethora of contracts anticipated with many clients requiring nanoemulsion product development, demonstrations, toll manufacturing services, and eventual lease/license agreements around our patented and revolutionary UltraShear technology platform. We are honored to welcome this new partnership with CBD Supply MD, a highly respected retail sales leader in the cannabis marketplace, especially in CBD products.”
To view the full press release, visit https://ibn.fm/WvUu2
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control biomolecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the biopharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to SYATF are available in the company’s newsroom at http://ibn.fm/PBIO
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork